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Rationale: Pulmonary embolism(PE)decreases theexhaledend-tidal
ratio of carbon dioxide to oxygen (etCO2/O2).
Objectives: To test if the etCO2/O2 can produce clinically important
changes in the probability of segmental or larger PE on computer-
ized tomography multidetector-row pulmonary angiography
(MDCTPA) in a moderate-risk population with a positive D-dimer.
Methods: Emergency department andhospitalizedpatientswithone
or more predefined symptoms or signs, one or more risk factors for
PE, and 64-slice MDCTPA enrolled from four hospitals. D-dimer
greater than 499 ng/ml was test(1), and D-dimer less than 500
ng/ml was test(2). The median etCO2/O2 less than 0.28 from seven
or more breaths was test(1) and etCO2/O2 greater than 0.45 was
test(2). MDCTPA images were read by two independent radiolo-
gists and the criterion standardwas the interpretation of acute PEby
either reader. PE size was then graded.
Measurements and Main Results: We enrolled 495 patients, including
60 (12%)with segmental or larger, and 29 (6%) with subsegmental
PE. A total of 367 (74%) patients were D-dimer(1), including all 60
with segmental or larger PE (posterior probability 16%). The
combination of D-dimer(1) and etCO2/O2(1) increased the poste-
rior probability of segmental or larger PE to 28% (95% confidence
interval [CI] for difference of 12%, 3.0–22%). The combination of
D-dimer(1) and etCO2/O2(2) was observed in 40 patients (8%;
95% CI, 6–11%), and none (0/40; 95% CI, 0–9%) had segmental or
larger PE on MDCTPA. No strategy changed the prevalence of
subsegmental PE.
Conclusions: Inmoderate-risk patientswith a positiveD-dimer, the et
etCO2/O2 less than 0.28 significantly increases the probability of
segmental or larger PE and the etCO2/O2 greater than 0.45 predicts
the absence of segmental or larger PE on MDCTPA.
Clinical trial registeredwithwww.clinicaltrials.gov (NCT00368836).
Keywords: fibrin fragment D; venous thromboembolism; medical
decision making; capnography; tomography, spiral computed
Multidetector-row computerized tomographic pulmonary angi-
ography (MDCTPA) has become a mainstay in diagnosis and
exclusion of acute pulmonary embolism (PE). Reasons for its
widespread adoption may include the perception of superior
diagnostic and operational test performance compared with
ventilation–perfusion lung scanning and the ability to show
alternative diseases (1). However, clinical trials have not found
superior outcome to MDCTPA compared with VQ scanning,
and MDCTPA imparts a higher lifetime risk of cancer from
radiation exposure and contrast nephropathy. The increasing
resolution afforded by 64-head computed tomography (CT)
equipment has produced a concomitant increase in the fre-
quency of PE diagnosis based on an isolated subsegmental
filling defect (2–7). The finding of an isolated subsegmental PE
on MDCTPA in the absence of a deep venous thrombosis
(DVT) confers significant diagnostic and therapeutic uncer-
tainty. The diagnostic uncertainty arises from the low interob-
server agreement between two radiologists for the interpretation
of isolated subsegmental PE (6–8). The therapeutic uncer-
tainty arises from the fact that many clinicians and authors
believe that patients with isolated subsegmental PE do not
benefit from anticoagulation, although no clinical trial has
tested this hypothesis (5, 9). In contrast, published guidelines
recommend immediate heparin anticoagulation for patients
with moderate to high suspicion of segmental or larger PE
and no contraindications to anticoagulation (10, 11).
Acute PE that obstructs a segmental or larger pulmonary
artery increases the volume of alveolar dead space in the lung to
an extent that can be measured. The alveolar dead space can be
estimated by simultaneously measuring the exhaled CO2 and
arterial blood partial pressure of CO2 (12). The alveolar dead
space can significantly improve the diagnostic performance of
the D-dimer as a screening tool for PE in the emergency
department (ED) setting (12–15). However, the requirement
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Pulmonary embolism (PE) that obstructs a segmental or
larger pulmonary artery increases alveolar dead space,
which leads to decreased exhaled CO2. The combination
of alveolar dead space plus D-dimer has been found to
accurately screen for acute pulmonary embolism. How-
ever, current methods of assessing alveolar dead space
require arterial blood sampling.
What This Study Adds to the Field
This study tests the diagnostic accuracy of a purely breath-
based, novel device that simultaneously measures exhaled
CO2/O2 ratio, as a noninvasive method to assess increased
alveolar dead space with segmental or larger PE. This
measurement does not require arterial blood sampling. The
combination of either a normal etCO2/O2 or a normal
D-dimer is associated with a very low rate of segmental or
larger PE.
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for simultaneous, steady-state measurement of exhaled CO2
and arterial blood CO2 represents a technical challenge and
causes pain to the patient. Accordingly, a purely breath-based
test that does not require a simultaneous blood sample would
have advantages. Patients with PE large enough to elevate the
alveolar dead space exhale breaths that are more like ambient
air—dilute in CO2 and higher in O2—when compared with
patients who have normal pulmonary ventilation–perfusion or
ventilation–perfusion mismatch caused by obstruction of the
airways. Several studies have found that a low exhaled, end-
tidal (et) CO2 measurement increases, and a normal or high
etCO2 decreases, the probability of acute PE in symptomatic
patients previously selected for PE evaluation (16, 17). Kline
and Hogg reported the end-tidal ratio of CO2/O2 had an
advantage over the etCO2 alone for the detection of acute
PE (18).
This study was conducted to test the incremental change in
posterior probability of PE produced by adding the etCO2/O2 to
the high-sensitivity, quantitative D-dimer (,500 ng/ml normal)
as a screening battery for patients with suspected PE. The a
priori, explicitly defined primary efficacy aims were to measure
the posterior probability of PE for the D-dimer test alone
compared with the following test combinations: (1) the D-dimer
greater than 499 ng/ml and etCO2/O2 less than 0.28, and (2) the
D-dimer less than 500 ng/ml or an etCO2/O2 greater than 0.45.
We hypothesized that the addition of etCO2/O2 to the D-dimer
would significantly increase the posterior probability of PE and
increase the proportion of patients who could have segmental or
larger PE ruled out before MDCTPA.
Some of the results of this study have been previously
reported in the form of an abstract (19) and in a published
report (7).
METHODS
Study Design
This was a prospective, four-center noninterventional, Food and Drug
Administration–regulated study of diagnostic accuracy of a proprietary
device conducted in accordance with the guidelines set out by the
Standards for Reporting of Diagnostic Accuracy criteria (20).
Study Setting and Population
Prospective enrollment occurred from EDs, wards, and intensive care
units of four academic medical centers in the United States (see online
supplement).
Because MDCTPA scans at the four sites were ordered in equal
proportions from the ED as for admitted inpatients, we enrolled
patients in approximately a 1:1 ratio from each location. Inclusion
criteria required that an MDCTPA be ordered as standard care, and
the patient had to have both one or more of 15 predefined signs or
symptoms of PE and one or more of 21 predefined known risk factors
for PE (see Table E1 in the online supplement) (7). All patients had
to provide written informed consent. Patients were excluded if they
could not provide follow-up or if they were incarcerated, pregnant,
hemodynamically unstable, unable to breathe through their mouth,
had fibrinolytic treatment within 48 hours, had PE diagnosed within
the last 6 months and were on anticoagulation or had a history of
noncompliance with anticoagulation for PE, or had known active
tuberculosis.
Study Protocol
MDCTPA images were obtained at each site as part of standard care,
and were done on 64-slice multidetector equipment with less than or
equal to 2.5 mm collimation. Details of image acquisition and in-
terpretation have been described (7).
Breath and blood collection. Breath and blood collection had to be
completed within 24 hours of MDCTPA completion in accordance
with standard operating procedures contained in the study binder.
Breath was collected and the etCO2/O2 analyzed using the Breath-
screen PE device, which used a computer algorithm to examine each
breath in real time to reject breaths with an alveolar volume less than
100 ml or less than 150% of the airway dead space volume (21). Seven
accepted breaths were required for per-protocol analysis. Blood was
analyzed for D-dimer (VIDAS ELISA; bioMerieux, Durham, NC)
using FDA-cleared devices (see online supplement).
MDCTPA interpretation. Images were interpreted by two indepen-
dent radiologists who were blinded to each other’s interpretations
(7). Images were interpreted as ‘‘No PE,’’ ‘‘Positive for acute PE,’’
‘‘Positive for chronic PE,’’ ‘‘Positive for other finding,’’ or ‘‘Indeter-
minate.’’ All scans read as positive for PE were further evaluated for
the percentage obstruction of the vessel(s) using the modified method
of Mastora and colleagues; PE was considered subsegmental for
a total percentage lung obstruction of less than 5% (22) (see online
supplement).
Criterion standard for acute PE. For the first analysis, the criterion
standard defined PE as present for any MDCTPA interpreted as
positive for acute PE by either or both radiologists together with
clinical decision to initiate and maintain anticoagulation. In the per
protocol analysis, the criterion standard for PE(1) was the interpre-
tation of a segmental or larger filling defect on MDCTPA(2).
Follow-up
Using previously described methods (23), we used a standardized
telephone survey to participants supplemented by review of updated
medical records to determine if any patients developed new PE or
DVT within 45 days after enrollment.
Data Analysis
The per-protocol primary efficacy aims were to measure the change in
posterior probability of PE when the etCO2/O2 was added to the D-
dimer for the detection of segmental or larger PE. The test-positive
comparison was ([D-dimer . 499 ng/ml] vs. [D-dimer . 499 ng/ml and
etCO2/O2 , 0.28]) and the test-negative comparison was ([D-dimer ,
500 ng/ml] vs. [D-dimer , 500 ng/ml or etCO2/O2 . 0.45]). We used
linear and logistic regression to test D-dimer and etCO2/O2 values as
independent variables for correlation with percentage pulmonary
vascular obstruction and prediction of PE diagnosis, as dependent
variables, respectively (see online supplement).
RESULTS
Figure 1 shows the flow diagram of patients starting with those
subjects screened for inclusion to the point of final outcome
with respect to PE diagnosis. A total of 547 patients signed
a consent form and 495 had complete data. Exclusions included
9 patients for whom a blood specimen could not be obtained, 7
other patients for whom seven accepted breaths could not be
obtained, and 11 other patients with missing blood and breath
samples. All 495 patients with complete data had both the D-
dimer assay performed and the etCO2/O2 measurement per-
formed. Breaths were collected in an average of 45 6 14
seconds and etCO2/O2 data are based on an average of 10.5 6
2.6 breaths. General demographic characteristics and clinical
characteristics of patients are shown in Table 1.
The criterion standard for acute PE was found in 89
MDCTA scans (either reader interpreted acute PE); chronic
PE was found in 4 others in the absence of any findings
suggestive of acute PE. Twenty-nine of 89 (32.5%) MDCTPA
scans demonstrated acute PE that was subsegmental. The mean
pulmonary vascular obstruction was 19.7 6 23.6% for the 89
scans with acute PE interpretations and 6.8 6 5.0% for the four
scans with chronic PE (see online supplement).
Compared with those without PE, patients with PE(1) had
significantly higher mean D-dimer (3,566 6 4,103 ng/ml
[PE(1)] vs. 1,468 6 2,141 ng/ml [PE(2)]) and significantly
lower etCO2/O2 values (0.32 6 0.08 vs. 0.35 6 0.09). First-order
regression analyses of the raw D-dimer and etCO2/O2 values
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versus percentage pulmonary vascular obstruction demon-
strated Pearson correlation coefficient (R2) equal to 0.11 for
D-dimer and 0.20 for etCO2/O2 (see online supplement). Trans-
formation of the D-dimer value into its natural logarithm
yielded R2 5 0.14. Multivariate logistic regression analysis
containing D-dimer, etCO2/O2, pulse rate, % SaO2, thrombo-
philia, age greater than 49 years, bed confinement more than 72
hours, recent surgery, active malignancy, estrogen use, and prior
venous thromboembolism found only the D-dimer and etCO2/
O2 to have significant predictive value (P , 0.05 for the
coefficient) (see online supplement)
Detection of Any Acute PE
Table 2 shows the diagnostic indexes and posterior probabilities
of PE that would have been produced by the D-dimer, etCO2/
O2 alone, and the combinations of these tests using the first
criterion standard. This table considers all 89 PE(1) scans as
criterion positive, including 29 MDCTPA scans with subseg-
mental-sized filling defects. The D-dimer was positive in 367
(74%) of the cohort, including 85 patients with PE, leading to
a posterior probability of PE of 23.2% (95% confidence interval
[CI], 18.9–27.8%) for a positive D-dimer. The D-dimer was
negative in 128/495 (26%; 95% CI, 18.3–25.0%), including four
patients with PE, leading to a posterior probability of 3.1%
(95% CI, 0.9–7.8%). These four had isolated subsegmental PE.
The addition of the etCO2/O2 to the D-dimer increased the
posterior probability of PE with a positive test result, and
expanded the proportion of the cohort with a negative test
result. First, from the 367 patients with a positive D-dimer, 95
also had an etCO2/O2 less than 0.28, including 33 who had PE,
leading to a posterior probability of 33/95 or 34.7% (95% CI for
the difference, 34.7223.2 5 11.5%, 1.6–22.4%). Second, when
Figure 1. Flow diagram
showing the number of pa-
tients screened, enrolled,
and reasons for exclusions.
CT 5 computed tomog-
raphy; PE 5 pulmonary
embolism.
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the 40 (8.1% of the cohort) patients who had a positive D-dimer
but had an etCO2/O2 greater than 0.45 were also considered test
negative in addition to the 128 patients with a negative D-dimer
(D-dimer , 500 ng/ml or etCO2/O2 . 0.45), the proportion of
patients with a negative combined test result was significantly
increased to 168/495 or 34.0% (95% CI for difference of 8.1%,
5.8–10.8%), and six of these 168 patients had PE, all six of which
were isolated subsegmental PE, resulting in a posterior proba-
bility for any PE equal to 6/168 or 3.8% (95% CI, 1.3–7.6%).
Further details of these six patients include a D-dimer greater
than 500 in three and an etCO2/O2 greater than 0.45 in three;
risk factors for PE of estrogen use (2), prior history of PE (1),
and active malignancy (1); one patient with COPD; and none
with DVT found on ultrasound.
Detection of Segmental or Larger PE
Table 3 shows the results of the per protocol analysis that
restricts the criterion standard for PE(1) to the 60 (12.1%)
patients with MDCTPA scans that demonstrated segmental or
larger filling defects. For the detection of segmental or larger
PE, the addition of the etCO2/O2 to the D-dimer increased both
the posterior probability of PE with a positive test result and the
proportion of the cohort with a negative test result. Of the 367
patients with a positive D-dimer, 60 had segmental or larger PE,
leading to a posterior probability of 16.3% (95% CI, 12.7–
20.5%). Among the 95 with both a positive D-dimer and an
etCO2/O2 less than 0.28, 27/95 (28.4%) had segmental or larger
PE, leading to a significantly increased posterior probability
compared with the prevalence of segmental or larger PE in the
entire cohort (95% CI for difference of 12.1%, 3.0–22.5%).
None of the 128 patients with a negative D-dimer and none of
the 53 patients with an etCO2/O2 greater than 0.45 had a seg-
mental or larger PE. Forty patients (8% of cohort) had D-dimer
greater than 499 ng/ml but had etCO2/O2 greater than 0.45.
Thus, the incremental value of the etCO2/O2 added to the
D-dimer in terms of the number needed to test to prevent one
MDCTPA was 12.3. In total, 168 patients had either the
D-dimer less than 500 ng/ml or the etCO2/O2 greater than
0.45, and none of these had segmental or larger PE. Thus, the
posterior probability of segmental or larger PE in patients with
the negative combined test(2) result (D-dimer , 500 ng/ml or
etCO2/O2 . 0.45) was 0/168 (95% CI, 0–2.2%).
Detection of Subsegmental and Chronic PE
The baseline frequency of isolated subsegmental PE discovered
on MDCTPA was 29/495 (5.8%). Had clinicians only ordered
MDCTPA scanning for patients with a positive D-dimer, then
the frequency of isolated subsegmental PE would have been
25/367 or 6.8%, and had they only ordered MDCTPA for
patients with a positive D-dimer and an etCO2/O2 less than
0.45, this frequency would have been 23/327 (7.0%). Among the
four patients with chronic PE and no evidence of acute PE, the
D-dimer was normal in one (350 ng/ml), and all four patients
had an etCO2/O2 less than 0.45.
Detection of Subsegmental PE with DVT
Of the 29 patients with subsegmental PE, 20 underwent venous
ultrasonography of the legs (one included the arms as well) and
TABLE 1. CLINICAL FEATURES OF THE PATIENT POPULATION
AT THE TIME OF ENROLLMENT
Feature N %
General characteristics
Age, mean, median (range), yr 495 54, 55 (18–94)
Female 311 63
Hispanic or Latino ethnicity 22 4
White 342 69
Black or African American 145 29
American Indian or Alaskan native 4 0.8
Native Hawaiian or native Pacific Islander 2 0.4
Asian 2 0.4
Enrolled in the ED 238 48
Enrolled as an inpatient 257 52
Signs and symptoms of PE
New-onset dyspnea 293 59
Pulse > 90 beats/min 289 58
Substernal chest pain 207 42
Cough 206 42
Respiratory rate . 20 breaths/min 197 40
Pulse oxygenation , 95% 185 37
Increased chronic dyspnea 77 16
Risk factors for PE
Age . 49 yr 335 68
Body mass index . 36 kg/m2 125 25
Bed rest or hospitalization . 48 h 83 17
Previous surgery within 4 wk 76 15
Active malignancy 68 14
Estrogen use 50 10
Indwelling deep venous catheter 47 9
Patient history of PE or DVT
PE . 6 mo on current treatment 14 3
DVT on current treatment 29 6
PE or DVT on no current treatment 51 10
Definition of abbreviations: DVT 5 deep venous thrombosis; ED 5 emergency
department; PE 5 pulmonary embolism.
TABLE 2. DIAGNOSTIC INDEXES FOR D-DIMER AND END-TIDAL RATIO OF CARBON DIOXIDE TO OXYGEN FOR ANY PULMONARY
EMBOLISM POSITIVE
Test Result
Test
Interpretation
Number with Result
Sensitivity Specificity
Likelihood Ratio Posterior Probability of PE
PE(1) PE(2) (1) (2) Test (1) Test (2)
D-dimer . 499 ng/ml (1) 85 282 95.5 30.5 1.37
0.15
23.2% 3.1%
D-dimer , 500 ng/ml (2) 4 124
95% CI 88.8–98.9 26.1–35.3 1.26–1.49 0.06–0.36 18.9–27.8% 0–7.8%
etCO2/O2 , 0.28* (1) 33 93 94.3 35.4 1.46
0.16
26.2% 3.8%
etCO2/O2 . 0.45* (2) 2 51
95% CI 80.8–99.3 27.6–43.8 1.23–1.70 0.04–0.54 18.8–34.8 0.5–13.0%
D-dimer . 499 and
etCO2/O2 , 0.28
(1) 33 62 84.6 72.3 3.06
0.21
34.7% 3.6%
D-dimer , 500 or
etCO2/O2 . 0.45
(2) 6 162
95% CI 69.5–94.1 66.0–78.1 2.35–3.91 0.10–0.41 25.3–45.2% 1.3–7.6%
Definition of abbreviations: CI 5 confidence interval; etCO2/O2 5 end-tidal ratio of carbon dioxide to oxygen; PE 5 pulmonary embolism.
* n 5 316 had an etCO2/O2 of 0.28 to , 0.45, of whom 54 were PE1 and 262 were PE2.
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9 others underwent CT venography within 10 days of enroll-
ment. Six patients had venous noncompressibility consistent
with DVT in the following veins: one in a brachial vein distal to
an indwelling catheter, two with isolated calf veins, and two
with isolated popliteal veins; one had both chronic femoral and
calf vein findings. All six of the patients with a positive
ultrasound had both a D-dimer greater than 499 ng/ml and an
etCO2/O2 less than 0.45.
PE and DVT on Follow-up
Within 45 days, eight patients who did not have any PE
diagnosis at enrollment had imaging performed as part of
standard care that suggested new PE (n 5 2) or DVT (n 5 6)
(Table 4). Three of these patients were prescribed anticoagula-
tion at enrollment, but their compliance with treatment was not
studied. Two of the 8 patients were prescribed new antico-
agulation because of the imaging results.
DISCUSSION
This study tested the hypothesis that when compared with the
D-dimer alone, the combination of D-dimer plus etCO2/O2
could produce clinically important improvements as a screening
strategy for segmental or larger PE before MDCTPA in
a moderate risk population. The main finding was that the
test-positive combination (D-dimer . 499 ng/ml and etCO2/
O2 , 0.28) produced a posterior probability of any PE equal to
34.7% and a posterior probability of segmental or larger PE
equal to 28.4%, representing a significant increase over the
posterior probability of PE observed with a positive D-dimer
alone in either case. The second main finding was that no
patient with a D-dimer less than 500 ng/ml and no patient with
an etCO2/O2 greater than 0.45 had a segmental or larger PE.
The test-negative combination (D-dimer , 500 ng/ml or etCO2/
O2 . 0.45) occurred in 168 patients (34% of the cohort). The
etCO2/O2 was test negative in 40 patients who had a positive
D-dimer and no segmental PE, equating to an absolute 8%
increase in the proportion of patients with a negative test
compared with a negative D-dimer alone. This suggests that
when added to the D-dimer, the etCO2/O2 could potentially
obviate approximately 1 in 12 MDCTPA scans performed with
the clinical question of whether or not the patient has segmental
or larger PE. None of the 168 patients with a negative combined
result had a segmental or larger PE. Multivariate logistic re-
gression containing the independent variables D-dimer, etCO2,
and 10 known strong clinical risk factors for PE (including
active cancer, recent surgery, and prior venous thromboembo-
lism) revealed that both the D-dimer and the etCO2/O2 had
significant independent predictive value for predicting any PE
on MDCTPA. These findings confirm that both the D-dimer
and etCO2/O2 predict the presence of a filling defect interpreted
as PE on MDCTPA independently of standard clinical factors
obtained at the bedside. First-order regression analysis demon-
strated that the etCO2/O2 had a higher Pearson correlation
coefficient (R2 5 0.20) than did the D-dimer (R2 5 0.08). These
findings suggest that the etCO2/O2 may be a better predictor of
the filling defect size on MDCTPA than the D-dimer.
The clinically oriented interpretations of these data are that
approximately one-third of MDCTPAs in this moderate- to
high-risk population could be avoided by the negative test
TABLE 3. DIAGNOSTIC INDEXES FOR THE D-DIMER AND END-TIDAL RATIO OF CARBON DIOXIDE TO OXYGEN FOR SEGMENTAL OR
LARGER PULMONARY EMBOLISM
Test Result
Test
Interpretation
Number with Result
Sensitivity Specificity
Likelihood Ratio Posterior Probability of PE
PE(1) PE(2) (1) (2) Test (1) Test (2)
D-dimer . 499 ng/ml (1) 60 307 100 29.4 1.42 0 16.3% 0.0%
D-dimer , 500 ng/ml (2) 0 128
95% CI 94.0–100 25.2–34.0 1.30–1.50 0–0.21 12.7–20.5% 0–2.8%
etCO2/O2 , 0.28* (1) 27 99 100 34.9 1.54 0 21.4% 0.0%
etCO2/O2 . 0.45* (2) 0 53
95% CI 87.2–100 27.3–43.0 1.28–1.72 0–0.36 14.6–29.6% 0–6.7%
D-dimer . 499 and
etCO2/O2 , 0.28
(1) 27 68 100 71.2 3.47 0 28.4% 0.0%
D-dimer , 500 or
etCO2/O2 . 0.45
(2) 0 168
95% CI 87.2–100 65.0–76.9 2.75–4.21 0–0.18 19.6–38.6% 0–2.2%
For definition of abbreviations see Table 2.
* n 5 316 had an etCO2/O2 of 0.28 to , 0.45, of whom 33 had segmental or larger PE and 283 had no PE or subsegmental PE.
TABLE 4. NEW VENOUS THROMBOEMBOLIC EVENTS WITHIN 45 DAYS AFTER ENROLLMENT
Site
Findings on Follow-up
Enrollment Findings
CTPA Readings D-Dimer etCO2/O2
Anticoagulation
Prescribed
Days Post
Enrollment CTPA/CTV
Venous
Ultrasound
New
Anticoagulation
Northwestern Neg/neg 818 0.266 Yes 9 Acute PE Negative NA
Carolinas Neg/neg 502 0.418 Yes 34 Chronic PE Not done NA
Northwestern Neg/neg 518 0.261 Yes 30 Not done Jugular and subclavian
thrombosis
NA
Wake Forest Neg/indeterminate 1,071 0.369 No 50 DVT Not done Yes
Carolinas Neg/neg 3,723 0.365 No 8 Negative Proximal leg Yes
Northwestern Neg/neg 298 0.396 No 16 Not done Chronic IJ No
Northwestern Neg/neg 2,429 0.212 No 18 Not done Axillary, cephalic Yes
Wake Forest Neg/neg 286 0.258 No 7 Not done Brachial vein No
Definition of abbreviations: CTPA5 computerized tomographic pulmonary angiography; CTV5 computerized tomographic venography; DVT5 deep venous thrombosis;
etCO2/O2 5 end-tidal ratio of carbon dioxide to oxygen; IJ 5 intrajugular; NA 5 not applicable (already anticoagulated); Neg 5 negative; PE 5 pulmonary embolism.
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combination defined by a D-dimer less than 500 ng/ml or an
etCO2/O2 greater than 0.45. Alternatively, the presence of a D-
dimer greater than 499 ng/ml and an etCO2/O2 less than 0.28,
together with a moderate to high clinical suspicion for PE, could
be interpreted as sufficient evidence to initiate anticoagulation
before imaging results, assuming the patient had no contrain-
dications. The clinical importance of these data depends in part
on the clinician’s perception of the clinical significance of the
isolated subsegmental PE, which is known to vary considerably
among clinicians (5). Published guidelines either imply that
isolated subsegmental PE does not warrant anticoagulation, or
remain silent on the issue, perhaps because of the lack of any
outcomes data (10, 11, 24, 25). We found that 29/89 (32.5%) of
patients with an MDCTPA interpreted as having acute PE by
either radiologist as having a total filling defect less than 5%,
suggesting smaller than segmental PE (see online supplement).
Our frequency of isolated subsegmental PE is higher than was
reported by Brunot and colleagues in 2005, who found 9 of 75
(12%) patients with PE observed on MDCTPA had isolated
subsegmental PE (6).
This work adds to published data showing that the addition
of the etCO2/O2 to pretest probability can produce very good
diagnostic accuracy in a lower-risk ED population (18). In
addition, the etCO2/O2 may represent a novel method to
monitor patients at high risk for PE who are about to engage
in surgery, chemotherapy, or other stressors that predispose to
PE. Kline and Hogg found that the relative preoperative to
postoperative change in etCO2/O2 was 1.6 6 20%, whereas the
relative change in D-dimer was 234 6 292% for patients
undergoing surgery believed to be high risk for VTE (26).
We believe this study design was rigorous in several unique
respects. The sample was multicenter. The enrollment methods
were highly planned in advance (see clinicaltrials.gov). We
designed the study to enroll a representative sample of patients
undergoing MDCTPA in current practice. Although the major-
ity of published studies of screening strategies for PE enrolled
only outpatients, we included an equal balance of inpatients and
ED patients. We submit that the primary effect of including
inpatients was to reduce the test specificity of both the D-dimer
and etCO2/O2, because inpatients may be more likely to have
elevated D-dimer concentrations and abnormal pulmonary
function than ambulatory patients. The inclusion criteria were
designed to produce a population that was at moderate risk for
PE. In addition to the requirement of an MDCTPA ordered as
standard care, we restricted enrollment to those patients with
explicitly documented signs or symptoms and at least one
known risk factor for PE. This resulted in a significantly higher
prevalence of any-size PE (18%; 95% CI, 15–22%) than the 8%
prevalence we recently found in a large, multicenter sample of
ED patients who enrolled on the basis of any test ordered for
PE (27). Recognizing the potential confounding effect of a very
low prevalence of PE was a major reason for restricting the
inclusion criteria to yield at least a moderate-risk population.
Limitations include the fact that this study only tests the
hypothetical contribution of the etCO2/O2 and does not test its
real-time use as a diagnostic instrument. In particular, a valida-
tion study must be performed to test if anticoagulation can be
safely withheld in patients with an etCO2/O2 greater than 0.45.
An important limitation to the potential diagnostic usefulness of
the etCO2/O2 ratio is that the majority of measurements, 316
(64%), were in an intermediate range (0.28 to , 0.45) and
therefore may not be helpful to decision making. The optimal
management of subsegmental PE also remains uncertain.
Although we collected data required for various pretest prob-
ability scoring systems, including the Wells criteria, we elected
to not include them. We collected pretest probability data after
the decision was made to order MDCTPA—a decision often
made by a clinical team. We submit that pretest probability data
need to be collected from the individual most responsible for
ordering the MDCTPA. However, in 40% of enrolled patients,
the research team was unable to determine the individual
clinician willing to take primary responsibility for ordering the
MDCTPA. Although we did perform detailed follow-up of all
patients out to 45 days, we did not include recurrent venous
thrombotic events in the criterion standard in this analysis.
In summary, this study found that the addition of an etCO2/
O2 less than 0.28 to a positive D-dimer significantly increases
the probability of a filling defect consistent with a segmental or
larger PE observed on MDCTPA, and that patients with either
a negative D-dimer or an etCO2/O2 greater than 0.45 had a very
low probability of segmental or larger PE on MDCTPA. We
conclude that the combined testing strategy of the D-dimer plus
the etCO2 produces clinically important advantages as a screen-
ing step before MDCTPA compared with the D-dimer alone.
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